What Boston Scientific's FY2025 10-K says: 12 signals
Boston Scientific filed its latest 10-K with the SEC on Feb 17, 2026. It discusses capex increase, product launch and acquisition announced.
Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn
- Filed
- Feb 17, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Boston Scientific's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Announced definitive agreement to acquire Penumbra, Inc. for $14.5B in January 2026.
This massive acquisition, funded partially by $11B in new debt, will trigger a significant post-merger integration effort.
$14.5B
Purchase price for acquisition of Penumbra, Inc.
Planning to issue approximately $11 billion in new debt to fund Penumbra acquisition
The company will be raising significant capital through new debt, indicating a need for financial advisory, legal, and banking services to structure and place the debt offering.
$11B
New debt to be issued to partially fund the Penumbra, Inc. acquisition
FARAPULSE PFA System sees rapid adoption after FDA and Japan PMDA approvals in 2025.
The FARAPULSE system is now the main revenue driver for the Electrophysiology unit, indicating a massive commercialization and manufacturing scale-up effort.
Pulsed Field Ablation (PFA)
Facing increased pricing pressure from low-cost manufacturers and local competitors in China
The company explicitly identifies competition from low-cost and domestic Chinese suppliers as a source of pricing pressure, creating a need for solutions that improve efficiency, demonstrate clear economic value, and differentiate their products to protect margins.
Completed acquisition of Bolt Medical in Q2 2025, integrating its advanced laser platform.
The completion of the Bolt Medical acquisition brings new intravascular lithotripsy technology into the portfolio.
intravascular lithotripsylaser
Launched WATCHMAN FLX Pro device in Europe after receiving CE mark in Q2 2025.
The European launch of the next-generation WATCHMAN device requires scaling up marketing, sales, and distribution efforts across the region.
Left Atrial Appendage Closure (LAAC)
Prioritizing global expansion, especially in emerging markets, as a core growth strategy.
Boston Scientific is focused on increasing net sales and market share in new global markets, including emerging markets.
Transforming R&D processes to drive efficiencies and achieve faster concept-to-market timelines.
The company is focused on optimizing its R&D cost structure and processes to accelerate product development.
Being fully self-insured for IP litigation increases financial risk from adverse legal decisions.
Completed acquisitions of Bolt Medical and SoniVie in Q2 2025 to expand technology portfolio
The company is actively acquiring technology to strengthen its market position, as shown by the recent acquisitions of Bolt Medical (lithotripsy platform) and SoniVie (ultrasound system).
intravascular lithotripsyintravascular ultrasound
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Boston Scientific with the Signal API
One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Boston Scientific 10-K
When did Boston Scientific file its latest 10-K?
What does Boston Scientific's latest 10-K say about restructuring?
Where can I find Boston Scientific's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .